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ABSTRACT
Animal studies implicate the AP-1 (activator protein-1) pro-inﬂammatory pathway as a promising
target in the treatment of atherosclerotic disease. It is, however, unclear whether these
observationsapplytohumanatherosclerosis.ThereforeweevaluatedtheproﬁleofAP-1activation
through histological analysis and tested the potential beneﬁt of AP-1 inhibition in a clinical trial.
AP-1 activation was quantiﬁed by phospho-c-Jun nuclear translocation (immunohistochemistry)
on a biobank of aortic wall samples from organ donors. The effect of AP-1 inhibition on
vascular parameters was tested through a double blind placebo-controlled cross-over study of
28 days doxycycline or placebo in patients with symptomatic peripheral artery disease. Vascular
function was assessed by brachial dilation as well as by plasma samples analysed for hs-CRP
(high-sensitivity C-reactive protein), IL-6 (interleukin-6), IL-8, ICAM-1 (intercellular adhesion
molecule-1), vWF (von Willebrand factor), MCP-1 (monocyte chemoattractant protein-1), PAI-1
(plasminogenactivatorinhibitor-1)andﬁbrinogen.Histologicalevaluationofhumanatherosclerosis
showed minimal AP-1 activation in non-diseased arterial wall (i.e. vessel wall without any signs of
atherosclerotic disease). A gradual increase of AP-1 activation was found in non-progressive and
progressive phases of atherosclerosis respectively (P<0.044). No signiﬁcant difference was found
between progressive and vulnerable lesions. The expression of phospho-c-Jun diminished as the
lesion stabilized (P<0.016) and does not signiﬁcantly differ from the normal aortic wall (P<0.33).
Evaluation of the doxycycline intervention only revealed a borderline-signiﬁcant reduction of
circulating hs-CRP levels (−0.51 μg/ml, P=0.05) and did not affect any of the other markers
of systemic inﬂammation and vascular function. Our studies do not characterize AP-1 as a
therapeutic target for progressive human atherosclerotic disease.
INTRODUCTION
Atherosclerosis is a lipid-driven disorder with a strong
inﬂammatory component. The efﬁcacy of lipid-lowering
interventions to reduce incident atherosclerotic disease
has been ﬁrmly established, yet its success rate remains
limited to an approximate 30% reduction in clinical
events [1]. Hence, the need for complementary strategies
beyond that of lipid lowering is widely acknowledged.
Inﬂammation is a key factor in the progression and
complications of atherosclerotic disease. Consequently,
strategies aimed at the ‘central hub’ of inﬂammation have
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been brought forward as a reasonable target in limiting
vascular inﬂammation [2]. In vitro and animal studies
implicate the common inﬂammatory transcription factor
AP-1 (activator protein-1) as a critical correlate in
the initiation and progression of vascular dysfunction,
and atherogenesis. Hence, AP-1 inhibition has been
proposed as an attractive target to prevent progression
of atherosclerosis [3–6].
However, as the available literature on the role of
the AP-1 pathways in human atherosclerosis is limited,
we decided to explore the possible role of AP-1 in
atherosclerotic disease. To that end, we ﬁrst performed
a systematic histological evaluation of AP-1 activation
in the successive stages of atherosclerotic disease. This
evaluationshowedabundantAP-1activationthroughout
all stages of atherosclerosis. We next performed a clinical
study to test whether quenching of AP-1 activation
improves vascular function. The tetracycline analogue
doxycycline has been shown to have a direct inhibitory
effectontheactivationofJNK1(c-JunN-terminalkinase
1) and JNK2, two key members of the AP-1 pathway
[7]. Thesein vitroﬁndings were corroboratedina clinical
studythatshowedthata2-weekdoxycyclineintervention
in patients with an AAA (abdominal aortic aneurysm)
quenches aortic wall AP-1 activation [8].
Hence it was reasoned that doxycycline provides a
means of evaluating a possible role of AP-1 in human
atherosclerosis. We therefore tested whether doxycycline
improves vascular function in high-risk patients (patients
withperipheralarterydisease)inadouble-blindplacebo-
controlled cross-over trial.
MATERIALS AND METHODS
AP-1 activation
All sample collection and handling were performed
in accordance with the guidelines of the Medical and
Ethical Committee in Leiden, The Netherlands and
the code of conduct of the Dutch Federation of
Biomedical Scientiﬁc Societies (http://www.federa.org/?
s=1&m=82&p=0&v=4#827).
A systematic analysis of AP-1 activation (phospho-c-
Jun) was performed on material from a large biobank of
aortic patches that were removed along with the kidney
during kidney explanation from heart-beating, brain-
dead multiple organ donors. All donors met the criteria
set by The Eurotransplant Foundation. The patches were
divided into 5 μm parafﬁn-embedded sections. The stage
ofatherosclerosisforeachsectionwasclassiﬁedaccording
to the modiﬁed classiﬁcation of the American Heart
Association proposed by Virmani et al. [9] (Table 1). All
analyses were performed on the dominant lesion in the
tissue section, i.e. the section showing the most advanced
grade of atherosclerosis. Details of the ﬁrst 260 cases in
this bank have been published previously [12].
In order to achieve balanced study groups, we
consecutively selected pre-classiﬁed samples for each
stage (Table 1) from the tissue bank. The sections were
stainedfortheidentiﬁcationofactivatedAP-1(phospho-
c-Jun, nuclear translocation using the anti-phos-
pho-c-Jun clone KM-1; Cell Signaling, 1:800 overnight).
Conjugated biotinylated anti-mouse IgG was used as
a secondary antibody. Sections were developed with
Nova Red (Vector Laboratories). Corroboration
with the downstream marker PAI-1 (plasminogen
activator inhibitor-1) was performed with an in-house
rabbit polyclonal antibody that recognizes both the free
and complex form [10,11]. Conjugated biotinylated anti-
rabbit anti-IgG (1:1000 dilution, Amersham Biosciences)
was used as secondary antibody. Sections were
counterstained with Mayer’s haematoxylin. Stained
sections were histologically analysed for positive nuclear
signallingandclassiﬁedaccordingtointensity.Thedegree
of AP-1 activity was assessed semi-quantitatively within
the atherosclerotic lesion: − (absent), +/− (<10% of
component area stained positively), + (10–50%) and
++(>50%).Intimal,medialandadventitiallayerswere
analysed separately. Particular interest was paid to the
various cell types present in the atherosclerotic lesion
[i.e.endothelialcells,monocytes/macrophagesandSMCs
(smooth muscle cells)].
An atherosclerotic lesion was deﬁned as the area
between the endothelium and internal elastic lamina over
a distance of 1 mm. In the presence of a necrotic core,
the distance was expanded by another 500 μmo nb o t h
sides of the necrotic core to include the adjacent shoulder
region [12].
Intervention study
An open crossover double-blind placebo-controlled trial
was used to evaluate the effect of doxycycline therapy
on vascular functioning (Dutch Trial Registry NTR1389
http://www.trialregister.nl/trialreg/admin/rctview.asp?
TC=1389). As current medical strategies focus on high-
risk patients, we recruited patients with symptomatic
PAD (peripheral arterial disease) from the outpatient
department of vascular surgery. PAD patients were
chosen for their condition, which is associated with a
high risk for CVD (cardiovascular disease) [13,14]. PAD
was conﬁrmed by a history of intermittent claudication
and an ankle-brachial pressure index <0.9. Patients
with a history of lower extremity revascularization
or endarterectomy, with diabetes mellitus or known
hypersensitivityfortetracyclinederivates,ortreatedwith
antibiotics or immunosuppressive agents were excluded
from participation in the study. In order to exclude
potentialeffectsofdifferentkindsordosesofcholesterol-
lowering agents all subjects were switched to, or started
with, simvastatin (40 mg/day) at least 4 weeks prior to
the start of study medication. All subjects participated in
two sessions and both received treatments of 28 days of
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Table 1 Qualitative phospho-c-Jun expression in endothelial cells, SMCs and monocytes/macrophages within the intimal
atherosclerotic lesions
Lesions are classiﬁed according the modiﬁed American Heart Association classiﬁcation by Virmani et al. [8]. ∗P <0.041 and ∗∗P <0.009 between the groups, as
determined by ANOVA. −, no expression of phospho-c-Jun; +/−,0 – 1 0% ;+, 10–50%; ++, >50%.
Phospho-c-Jun expression
Morphological description n Cell type...Endothelial cells SMCs∗ Monocytes/macrophages∗∗
Normal aorta 10 +/−+ /−−
Non-atherosclerotic lesions
Adaptive intimal thickening 10 +/−+ −
Intimal xanthoma 10 +/−+ +
Progressive atherosclerotic lesions
Pathological intimal thickening 10 +/−+ + +
Early ﬁbroatheroma 10 ++ + /−
Late ﬁbroatheroma 10 ++ + /−
Vulnerable atherosclerotic lesions
Thin cap ﬁbroatheroma 10 ++ + +
Plaque rupture 8 ++ +
Stabilized atherosclerotic lesions
Healed ruptures 10 +/−+ +
Fibrotic calciﬁed plaque 10 +/−+ + /−
doxycycline (100 mg/day) (t 1
2 =15–23 h) or placebo in a
cross-over design. Dosing was separated by a washout
period of 28 days.
Informed consent was obtained from each patient.
Randomization was performed by the Leiden University
Medical Center pharmacy.
Brachial ﬂow-mediated dilation
Endothelial function was evaluated through ﬂow-
mediated vasodilation of the brachial artery, an
established test that assesses the vasodilatory response
to transient ischaemia. Endothelium independent vas-
odilation of the brachial artery was assessed through the
artery’s vasodilatory response to NTG (nitroglycerine)
[15]. Flow- and NTG-mediated vasodilations were
measured on each visit.
After overnight fasting, patients were examined in the
supine position after 15 min of rest in a quiet room at
room temperature. Patients refrained from vasoactive
drugs, coffee and tea for at least 8 h prior to testing.
The right brachial artery was visualized in longitudinal
sections above the elbow, by high-resolution ultrasound
using a 10 MHz linear probe on an Aloka 5500 SSD
machine. Reactive hyperaemia was triggered by inﬂating
a pneumatic tourniquet distal to the brachial artery to
50 mmHg above the systolic pressure for 5 min and
dilation of the vessel was evaluated 1 min after releasing
the tourniquet. The diameter of the brachial artery was
measured in triplicate at the R-wave of the ECG, at
the interface of the intima and media of the anterior
and posterior wall. The brachial artery was allowed to
returntoitsrestingstateforatleast15 min.Endothelium-
independent vasodilation was studied by brachial artery
diameter changes 4 min after administering 400 μgo f
NTGsublingual.Theinter-andintra-observervariability
for the measurement of the diameter of brachial artery
was <0.1 mm. Flow-mediated vasodilation and NTG-
mediated vasodilation were deﬁned as the percentage
increase in artery diameter during dilation.
Endothelium and inﬂammation
Fasting blood samples were taken from the patients’ left
arm(non-studyarm)justafterevaluatingvascularreactiv-
ity. Samples were centrifuged at 2000 g at 4◦C for 20 min
and the obtained plasma was removed and subsequently
recentrifuged at 12000 g for 10 min. Plasma was stored at
−80◦C until analysis. Glucose, insulin, hs-CRP (high-
sensitivity C-reactive protein), TAG (triacylglycerol),
HDL (high-density lipoprotein)-cholesterol and total
cholesterol concentrations were determined in one batch
at the certiﬁed clinical laboratory of the Leiden Univer-
sity Medical Center. The plasma concentration of LDL
(low-densitylipoprotein)-cholesterolwasobtainedusing
Friedewaldestimation.TheplasmaconcentrationofvWF
(von Willebrand factor), ICAM-1 (intercellular adhesion
molecule-1), PAI-1, MCP-1 (monocyte chemoattractant
protein-1), IL (interleukin)-6, IL-8, hs-CRP and ﬁbrino-
gen were obtained using ELISA [an in-house ELISA
using a rabbit anti-human vWF (A0082; Dako) and an
HRP (horseradish peroxidase)-conjugated rabbit anti-
human VWF antibody (P0226; Dako), an R&D Systems
humanICAM-1ELISA(DY720),anin-houseELISAus-
ingaPAI-1coatingmonoclonalantibody3-3bconjugate,
an R&D Systems human MCP-1 ELISA (DY279), a
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Sanquin PeliKine-compact human IL-6 ELISA (M1916),
aSanquinPeliKine-compacthumanIL-8ELISA(M1918)
and an in-house ELISA using a ﬁbrinogen coating α-
XDP conjugate]. hs-CRP was measured on a cobas
c system (04628918; Roche Diagnostics). vWF was
calibrated against a pool of human plasma (available from
Sanquin). All other calibrating solutions were supplied
within the kit. Samples were diluted to maintain plasma
concentration well within the accuracy boundaries of
the kits. All samples were analysed in duplicate. The
reproducibility and accuracy of the ELISA tests were
within the limits of the standard kit.
Statistical analysis
Mean levels of AP-1 expression in the immuno-
histochemical analysis were compared with the one-way
ANOVA. Differences between the groups were assessed
by Fisher’s LSD (least signiﬁcant difference) analysis.
P<0.05 was considered statistically signiﬁcant.
Power calculation for the crossover study was based
on data published in [7,14]. A group size of 12 patients
allowedforadiscriminatingpowerofmorethan95%for
a 20% difference in arterial dilation [17] and reduction
of pro-inﬂammatory cytokines [8] between placebo
and therapeutic treatment. The normality of different
variables was tested. Wilcoxon signed ranks test was used
if normal distribution of the data was not applicable (see
Table 3). Statistical signiﬁcance was deﬁned as a two-
sidedP<0.05.DataintheFiguresarepresentedasmeans
(S.D.) in Table 2 or as medians (25th and 75th percentiles)
in Table 3). All statistical analyses were performed using
SPSS for Windows, version 17.0.
RESULTS
Immunohistochemistry
AP-1 activation (phospho-c-Jun nuclear translocation)
was evaluated in 98 human aortic wall samples that cover
the full spectrum of atherosclerotic disease (Table 1).
Minimum activation of AP-1 was found in the normal
aortic wall. In these samples, nuclear staining was
mainly limited to the endothelial cells (Table 1 and
Figure 1). A gradual increase of AP-1 activation
was found in non-progressive and progressive phases
of atherosclerosis respectively (P<0.33 and P<0.044
respectively;Figure2),withinvolvementofmacrophages
and SMCs (Table 1 and Figure 1). No further signiﬁcant
increase was found in the vulnerable lesion types
(P<0.48; Figure 2). In advanced lesions (i.e. progressive
and vulnerable phases), activated cells were distributed
throughout the vascular wall with a particular strong
nuclear staining of macrophages and SMCs (Table 1
and Figure 1). A notable sharp reduction in AP-1
activation was found in the stabilized lesion types, i.e.
healed ruptures and ﬁbrotic calciﬁed plaques (P=0.016;
Figure 1 Phospho-c-Jun expression during the evolution of
human atherosclerosis
The intima within the normal aortic wall and in aortas containing adaptive intimal
thickening showed minimal expression of phospho-c-Jun in the nuclei of the
vascular SMC (A). There was a higher amount of phospho-c-Jun expression in the
inﬁltrating SMCs and monocytes surrounding the lipid pools in pathological intimal
thickening (B). In early ﬁbroatheromata almost 50% of the monocytes and
macrophages stained positive for phospho-c-Jun (C). In the thin cap ﬁbroatheroma,
the vulnerable phase in atherosclerosis, the very few SMCs that were found
within the ﬁbrous cap lacked phospho-c-Jun expression (D). In the ﬁbrous cap of
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Figure 2 Phospho-c-Jun expression within the various
atherosclerotic lesions
There was minimal phospho-c-Jun (p-c-JUN) expression within the endothelial cells
and SMCs of the normal aortic wall. This expression increased gradually during the
development of atherosclerosis. Activation of phospho-c-Jun increased signiﬁcantly
from non-progressive to progressive lesions (∗P <0.044). No signiﬁcant difference
was found between progressive and vulnerable lesions (P <0.48). The expression
of phospho-c-Jun diminished as the lesion stabilized (∗∗P <0.016) and did
not signiﬁcantly differ from the normal aortic wall (P <0.33). Values are
means+ −S.E.M. For the detailed qualiﬁcation scale, see the Materials and methods
section.
Figures 1 and 2). AP-1-regulated PAI-1 gene expression
showed a distribution parallel to the activated AP-1
expression, with a signiﬁcant increase in the progressive
lesions (P<0.002; Figure 3).
Doxycycline intervention
A total of 15 patients were enrolled in the study.
One patient experienced photosensitivity reaction and
withdrew from the study. No other adverse events
occurred. Two subjects were lost to follow up for
reasons that were not study related. The mean age of
the participants was 67+ −8 years and 82% were male.
All characteristics were assessed just prior to the start
of the study (Table 2). Evaluation of systemic markers of
inﬂammation (hs-CRP, IL-6, IL-8 and ﬁbrinogen) only
revealed a borderline signiﬁcant decrease in plasma hs-
CRP concentration after doxycycline treatment (−0.51
μg/ml, P=0.050; Table 3). Endothelial cell activation
markers (ICAM, vWF and PAI-1) were not inﬂuenced
by the treatment (Table 3).
healed atherosclerotic ruptures was a remarkable difference in phospho-c-Jun
expression between the SMCs in the remnants of the old cap and the newly formed
cap (E). Fibrotic calciﬁed lesions were mostly acellular and minimally expressed
phospho-c-Jun (F). +, phospho-c-Jun-positive SMC; −, phospho-c-Jun-negative
SMC; <, phospho-c-Jun-positive monocyte or macrophage.
Figure 3 PAI expression within the observed lesion in
relation to the atherosclerotic stage
There is a signiﬁcant increase in PAI expression when atherosclerosis evolves
from a non-progressive lesion into a vulnerable lesion (∗P <0.002). Values are
means+ −S.E.M. For the detailed qualiﬁcation scale and an overview of the various
atherosclerotic clusters, see the Materials and methods section.
Table 2 Patient characteristics
Values are means (S.D.), n=12. BMI, body mass index; DM, diabetes mellitus;
TAG, triacylglycerol.
Characteristic
Age (years) 67 (8)
Male gender 82%
BMI (kg/m2) 25.0 (5.0)
Smoking (%) 100
DM (%) 0.0
Total cholesterol (mmol/l) 4.37 (0.85)
TAG (mmol/l) 1.62 (1.62)
HDL (mmol/l) 1.26 (0.50)
Glucose (mmol/l) 5.95 (0.54)
Brachial artery diameter (mm) 3.8 (0.6)
In addition to the circulating inﬂammatory and
endothelialcellactivationmarkers,wealsoassessedﬂow-
mediated vasodilation as a functional test of endothelial
function. Flow-mediated vasodilation (baseline value,
13.2%) and NTG-mediated vasodilation (baseline
value, 11.3%) were not inﬂuenced by doxycycline
treatment[−5.9%(−14.9to3.9),P=0.10;and −5.4%
(−16.4 to 0.7), P=0.18; values are medians (25th to 75th
percentiles)] (Table 3).
DISCUSSION
Modulation of chronic vascular inﬂammation is now
considered the most promising complementary strategy
for the prevention of incident CVD. Typically, this
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Table 3 Markers of inﬂammation and vascular function
Values are medians (25th–75th percentile), n=12. Doxycycline−placebo represents the difference between the doxycycline treatment and the placebo treatment.
P <0.05 for doxycycline–placebo. ND, non-detectable; concentration below the detection limit of the assay (<20 pg/ml).
Parameter Baseline Doxycycline−placebo P
Circulating markers
hs-CRP (μg/ml) 2.21 (1.28–5.20) −0.51 (−6.46 to 0.04)∗ 0.05
Fibrinogen (mg/ml) 5.38 (3.89–6.23) −1.12 (−0.53 to 3.00) 0.18
IL-6 (pg/ml) 1.80 (0.92–2.03) −0.11 (−1.38 to 2.54)∗ 0.33
IL-8 (pg/ml) 4.28 (3.24–7.74) 0.68 (−1.38 to 2.54) 0.53
MCP-1 (pg/ml) ND −−
ICAM-1 (102 ng/ml) 1.88 (1.37–2.17) −0.13 (−0.36 to 0.34) 0.35
vWF (% HPP) 149.6 (114.3–164.5) −16.8 (−58.9 to 27.6) 0.58
PAI-1 (ng/ml) 34.4 (26.2–49.7) 4.6 (−20.5 to 46.1) 0.58
Dilation
Flow-mediated (%) 13.2 (6.9–16.4) −5.9 (−14.1 to 3.9) 0.10
NTG-mediated (%) 11.3 (8.8–25.1) −5.4 (−16.4 to 0.7) 0.18
∗Exclusion of a patient in the placebo arm with elevated levels of hs-CRP and IL-6 due to infection.
strategy will focus on patients with clinical or subclinical
atherosclerosis,i.e.thosewithprogressiveatherosclerotic
lesions. On the basis of animal studies, the AP-1
pro-inﬂammatory pathway has been implicated in the
initiation and progression of atherosclerotic disease. Up-
regulation of AP-1 in rabbits increased with age-related
vascular SMC proliferation [18,19] and in rats AP-1
mediated AngII (angiotensin II)-induced inﬂammation
[20].Additionally,ithasbeenshownthatAP-1deﬁciency
protects against the development of atherosclerosis in
hypercholesterolemic mice [5]. In humans, AP-1 was
activated in progressive and unstable atherosclerotic
plaques and proposed as a switch for inﬂammatory tissue
response and repair [21,22].
Consequently,thesestudiesimplyAP-1asareasonable
target for complementary therapeutic strategies, but its
potential role in human atherosclerosis remains unclear.
Our histological analysis shows a gradual increase in
theactivationoftheAP-1systemduringthedevelopment
of atherosclerotic disease, from normal up to progressive
atherosclerotic lesions. Remarkably, further transition
from progressive to vulnerable lesion types is not
associated with signiﬁcant increase of AP-1 activation.
This ‘plateau phase’ of activation clearly diminishes
in the ﬁbrotic calciﬁed stabilized plaques. The extent
of activation of the AP-1 system is paralleled by a
shift in activated cell types, from mainly endothelial
cells in normal tissue to predominantly vascular SMCs
in advanced atherosclerotic lesions. Accordingly, these
observations suggest that AP-1 activation is an early
event in human atherosclerotic disease and that it is
not prominently involved in further progression of the
disease (advanced atherosclerosis and its complications).
In order to further test or refute a possible role
of AP-1 activation in the perpetuation of advanced
atherosclerosis, we performed an intervention study
with doxycycline in a group of patients with PAD.
The presence of PAD identiﬁes patients with systemic
atherosclerosis at a high risk of cardiovascular events,
as reﬂected by general endothelial dysfunction and
a high incidence of myocardial infarction and stroke
[13,14]. This endothelial impairment is related to the
severity of the circulatory failure in the affected limb
and with increased plasma markers of inﬂammation
[23], and is a potentially reversible manifestation of
progressive vascular disease [24,25]. Flow- and NTG-
mediatedvasodilationofthebrachialarteryareespecially
suitable to detect changes in endothelial functioning and
have been reported as a widely used research tool and a
marker of cardiovascular atherosclerosis [13,26,27].
Independentoftheirantibioticproperties,doxycycline
and other members of the tetracycline family of antibiot-
icshavebeenrecognizedaspotentanti-inﬂammatoryand
immunomodulating agents [28–31]. Sub-antimicrobial
dosesofdoxycyclinearenowregisteredforthetreatment
ofactiveperiodontitisandrosacae[32,33].Invitrostudies
have shown that the effects are (in part) related to
an effect on the AP-1 inﬂammatory pathway. In fact,
doxycycline appeared equally effective as the established
AP-1 inhibitor SP600125 [7].
Doxycycline is safe and has an excellent tissue
penetration [34,35], making it a suitable candidate
for clinical studies. We previously studied the effects
of 2 weeks of perioperative doxycycline treatment
on vascular inﬂammation in AAA, and found that
doxycycline has a profound but selective effect on
vascularinﬂammation,asindicatedbyaclearreductionin
aorticwallIL-6andIL-8levels,andarespective75%and
96% reduction in aortic wall neutrophil and cytotoxic T-
cell content. Further evaluation showed that this effect
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is mediated by a selective reduction in AP-1 activation
(measured by phospho-c-Jun) [8]. Baseline AP-1 (non-
phosphorylated c-Jun) levels were not inﬂuenced by
doxycycline treatment. As such these clinical ﬁndings
corroborate the in vitro ﬁndings of Kim et al. [7], and
we thus hypothesized that doxycycline provides a means
of modulating AP-1 activation in atherosclerosis.
Despite the clear effects in aneurysmal disease, we did
not observe any effect on each of the markers studied
in the atherosclerotic patients. It is unlikely that failure
of the intervention reﬂects a pharmacokinetic limitation.
Our studies in AAA show that a brief period of 2 weeks
(i.e.onehalfofthetreatmentperiodinthisstudy)sufﬁces
for a profound effect. In these studies, we also observed
that the effect was already maximal at doses as low
as 50 mg. A more likely explanation for the failure of
doxycycline in our patients are the profound differences
in the inﬂammatory footprint between aneurysmal
disease and atherosclerotic disease, with AP-1 being
prominently involved in aneurysmal disease, but to a
much lesser extend in advanced atherosclerotic disease
[36].Wecannotfullyexcludethatthenegativeﬁndingsare
basedonatypeIIstatisticalerror;however,thestudywas
powered on results from a previous positive study [8]. As
of the consistent negative ﬁndings for all markers studied
andthecross-overdesign,itisinouropinionunlikelythat
a larger study would have signiﬁcantly different results.
The study does not support a major role for AP-1 in the
initiation and progression of atherosclerosis.
Our results do not exclude that AP-1 inhibition has a
beneﬁcial effects in the earliest phases (initiation phase)
of the disease. However, given the fact that manifest
atherosclerotic disease is present in more than 75% of
male population between 20 and 30 years of age [37],
such a treatment should typically be initiated before the
age of 20 years, and be maintained throughout the rest of
life. We consider such a strategy unrealistic.
Our ﬁndings do not exclude a role of AP-1 in
complications of atherosclerotic disease such as plaque
rupture. It has been suggested before that doxycycline
decreases the risk of acute coronary syndromes
[38]. Thrombo-occlusive events usually occur in the
vulnerablestagesoftheatheroscleroticprocess,including
plaque rupture and erosion. Plaque rupture is an acute
event with inﬂammatory characteristics distinctive from
progressive lesions. Given the presumably acute nature
of this process, this will be typically missed in our cross-
sectional sample collection.
In conclusion, the response to inhibition of the
activated AP-1 system is largely missing in the advanced
stages of human atherosclerosis. The results of our
intervention seemingly contrast with animal studies,
in which AP-1 deﬁciency in hypercholesterolaemic
mice ultimately prevented atherosclerosis. These results,
however, apply to the initiation of the atherosclerotic
process, whereas human atherosclerotic disease reﬂects
the advanced (i.e. progressive and vulnerable) stages.
This is in line with our systematic evaluation of AP-1
activationinthesuccessiveatheroscleroticstagesshowing
thatAP-1activation occurs earlyintheprocess andis not
related to advanced atherosclerosis and complications.
The mere presence of AP-1 in progressive human
atherosclerotic tissue is not an indication of the extent
of the disease process.
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